United States· US:0597-0485_72dd9ccf-66f7-47a4-b6e4-4bb2f9a1caa3
Cyltezo
A medicinal product containing adalimumab-adbm, registered in United States by Boehringer Ingelheim Pharmaceuticals, Inc..
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- adalimumab-adbm
- Manufacturer
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- June 3, 2026
Packs & prices · 1
- ndc1105970485202 KIT in 1 CARTON (0597-0485-20) / 1 KIT in 1 KIT * 1 SYRINGE in 1 TRAY (0597-0480-12) / .4 mL in 1 SYRINGE * 2 PACKET in 1 TRAY / 1 mL in 1 PACKET
Regulatory notes
Same medicine, other countries
Adalimumab-adbm in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaAMGEVITAAmgen Europe B.V., Breda
- FinlandAMGEVITAAmgen Europe B.V.
- SwitzerlandAbrilada
- BelgiumAmgevita 20 mgAmgen Europe
- SwedenAMGEVITA 20 mg Injektionsvätska, lösning i förfylld sprutaAmgen Europe B.V.
- IcelandAmgevitaAmgen Europe B.V.*
- NetherlandsAmgevita 20 mg, oplossing voor injectie in een voorgevulde spuitAmgen Europe B.V.
- FranceAMGEVITA 20 mg, solution injectable en seringue préremplieAMGEN EUROPE
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Hukyndra, Humira
- Iceland · Amgevita, Amsparity
- Liechtenstein · Amsparity, Hefiya
- Norway · Amgevita, Amsparity
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ded803a3-1798-4551-b01c-53828fb29783 GET /v1/drugs/ded803a3-1798-4551-b01c-53828fb29783?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": null,
"spl_meta": {
"115ea79b-7209-7f19-b35d-36ec0828fbf5": {
"match": "brand_token",
"title": "CYLTEZO (ADALIMUMAB-ADBM) KIT [BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.]",
"spl_version": "17",
"published_date": "2026-03-09"
}
},
"productid": "0597-0485_72dd9ccf-66f7-47a4-b6e4-4bb2f9a1caa3",
"productndc": "0597-0485",
"dosage_form": "KIT",
"dea_schedule": null,
"product_type": "HUMAN PRESCRIPTION DRUG",
"substance_name": null,
"proprietary_name": "Cyltezo",
"active_ingred_unit": null,
"application_number": "BLA761058",
"marketing_category": "BLA",
"nonproprietary_name": "adalimumab-adbm",
"start_marketing_date": "20240430",
"active_numerator_strength": null
}See everything about adalimumab-adbm.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.